Hemani Sunita Ali, Glover Brianna, Ball Samantha, Rechler Willi, Wetzel Martha, Hames Nicole, Jenkins Elan, Lantis Patricia, Fitzpatrick Anne, Varghese Sarah
Division of Hospital Medicine
Children's Healthcare of Atlanta, Atlanta, Georgia.
Hosp Pediatr. 2021 Nov;11(11):1263-1272. doi: 10.1542/hpeds.2020-004788. Epub 2021 Oct 5.
Extensive literature supports using dexamethasone (DEX) in children presenting to the emergency department (ED) with mild-to-moderate asthma exacerbations; however, only limited studies have assessed this in hospitalized children. In this study, we evaluate the outcomes of DEX versus prednisone/prednisolone (PRED) use in children hospitalized for mild-to-moderate asthma exacerbations.
This multisite retrospective cohort study included children between 3 and 21 years of age hospitalized to a tertiary care children's hospital system between January 1, 2013, and December 31, 2017, with a primary discharge diagnosis of acute asthma exacerbation or status asthmaticus. Primary study outcome was mean hospital length of stay (LOS). Secondary outcomes included PICU transfers during initial hospitalization and ED revisits and hospital readmissions within 10 days after discharge. Generalized linear models were used to model logged LOS as a function of steroid and demographic and clinical covariates. The analysis was stratified by initial steroid timing.
Of the 1410 children included, 981 received only DEX and 429 received only PRED. For children who started oral steroids after hospital arrival, DEX cohort had a significantly shorter adjusted mean hospital LOS (DEX 24.43 hours versus PRED 29.38 hours; = .03). For children who started oral steroids before hospital arrival, LOS did not significantly differ (DEX 26.72 hours versus PRED 25.20 hours; = .45). Rates of PICU transfers, ED revisits, and hospital readmissions were uncommon events.
Children hospitalized with mild-to-moderate asthma exacerbations have significantly shorter hospital LOS when starting DEX rather than PRED on admission.
大量文献支持在急诊科就诊的轻至中度哮喘急性发作儿童中使用地塞米松(DEX);然而,仅有有限的研究对住院儿童进行过评估。在本研究中,我们评估了在因轻至中度哮喘急性发作住院的儿童中使用DEX与泼尼松/泼尼松龙(PRED)的效果。
这项多中心回顾性队列研究纳入了2013年1月1日至2017年12月31日期间在一家三级儿童专科医院系统住院的3至21岁儿童,其主要出院诊断为急性哮喘发作或哮喘持续状态。主要研究结局为平均住院时间(LOS)。次要结局包括初次住院期间转入儿科重症监护病房(PICU)的情况、急诊复诊以及出院后10天内再次入院的情况。使用广义线性模型将记录的LOS作为类固醇、人口统计学和临床协变量的函数进行建模。分析按初始类固醇给药时间分层。
纳入的1410名儿童中,981名仅接受DEX治疗,429名仅接受PRED治疗。对于入院后开始口服类固醇的儿童,DEX组调整后的平均住院LOS显著缩短(DEX为24.43小时,PRED为29.38小时;P = 0.03)。对于入院前开始口服类固醇的儿童,LOS无显著差异(DEX为26.72小时,PRED为25.20小时;P = 0.45)。转入PICU、急诊复诊和再次入院的发生率均较低。
因轻至中度哮喘急性发作住院的儿童入院时开始使用DEX而非PRED时,住院LOS显著缩短。